Intuitive Surgical, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David J. Rosa
- Full Time Employees
- 17,021
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1020 Kifer Road Sunnyvale CA United States of America 94086-5304
- IPO Date
- Jun 16, 2000
- CIK
- 0001035267
- Website
- intuitive.com
- Similar Companies
- Business
- Intuitive Surgical, Inc. develops, manufactures, and markets advanced robotic-assisted surgical systems designed to enhance the quality and access to minimally invasive care globally. Its core products include the da Vinci Surgical System, which enables surgeons to perform a wide range of complex surgical procedures across specialties such as general surgery, urology, gynecology, cardiothoracic, and head and neck surgery using minimally invasive techniques. The company also offers the Ion Endoluminal System, a robotic platform for diagnostic endoluminal procedures enabling minimally invasive lung biopsies through advanced imaging and navigation technology. Intuitive’s product suite includes stapling, energy, and core instrumentation compatible with its multi-port da Vinci systems, alongside progressive learning pathways that facilitate clinical adoption, and a comprehensive infrastructure of service and support including installation, maintenance, technical support, proactive system health monitoring, and integrated digital capabilities that provide hospitals with data-driven insights to optimize surgical performance. Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical operates globally, supporting hospitals and surgical teams across over 60 countries. In the last 1-2 years, the company has advanced the commercial launch of its da Vinci 5 Surgical System, receiving regulatory clearances from the US FDA and CE mark in 2024, with 2025 focused on scaling the adoption of this platform through enhanced hardware and software upgrades featuring increased computing power and digital capabilities. Intuitive reported significant growth in system placements and procedure volumes, with a 14% year-over-year increase in installed base and 17% procedural growth as of mid-2025. Strategic priorities include expanding its robotic surgery ecosystem, reinforcing its recurring revenue model—which accounted for 84% of revenue in 2024—and furthering its Quintuple Aim framework aimed at improving patient outcomes, care team experience, access to care, and lowering total costs. Additionally, leadership transitioned in mid-2025 with President Dave Rosa promoted to CEO, signaling a new phase of growth and innovation focus. Despite rising competition in the robotic surgery field, Intuitive remains a dominant market leader through continuous technological innovation and strategic expansion. This comprehensive offering positions Intuitive Surgical as a pioneer and global leader in robotic-assisted, minimally invasive surgical technology, serving healthcare providers with products, services, and digital innovations that collectively enhance surgical precision, patient recovery, and overall healthcare system efficiency.
Company News
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
2 Beaten-Down Stocks to Buy Before They Bounce Back
Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth
Ambulatory Surgery Centers Are Becoming ISRG's New Growth Engine
ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions
Intuitive Surgical, Inc. (ISRG) Rises As Market Takes a Dip: Key Facts
Can AI Keep ISRG Ahead of Rising Robotic Surgery Competition?
Robots Everywhere: Goldman Sachs Now Sees 6.5 Million Humanoid Robots by 2035
Intuitive Surgical Sees Procedure Growth Despite U.S. Slowdown and China Pressure
This AI ETF Is Missing the Biggest AI Winners
Intuitive Surgical, Inc. (ISRG) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Brokers Suggest Investing in Intuitive Surgical (ISRG): Read This Before Placing a Bet
ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?
Here's Why Intuitive Surgical, Inc. (ISRG) Fell More Than Broader Market
New meta-analysis shows statistically significant improvements in patient outcomes associated with da Vinci surgery versus laparoscopic and open surgery across 13 common benign conditions
ISRG's Ion Platform Is Quietly Becoming a Second Growth Engine